Published November 17, 2026
In 1983, when November was designated Alzheimer’s Disease Awareness Month, fewer than two million Americans had been diagnosed, and the disease was poorly understood. Today, we know much more about it, but, sadly, far more Americans are living with the diagnosis. There is still no cure, but there is now a reason not to wait for treatment. Diagnosed early, Alzheimer's can be slowed.
By most accounts, Americans are living longer, and longer lives bring more of the diseases of aging, including dementia, stroke and Parkinson’s disease, to our communities. Dementia is an umbrella term for a brain condition that causes a loss of memory and thinking abilities. Simply put, it is the loss of the ability to form and manage memories.
According to the Alzheimer’s Association, more than seven million Americans over age 65 live with dementia, at a direct care cost of over a billion dollars. In Connecticut, approximately 80,000 people live with dementia, and an estimated 60,000 of them have Alzheimer's disease.
Dementia refers to any cognitive decline regardless of the cause. The most common cause of dementia is Alzheimer’s disease, which is why the two terms are often used interchangeably. Other causes include vascular disease (an accumulation of mini strokes in the brain), inflammation, metabolic problems and traumatic brain injury.
Symptoms of Alzheimer’s disease progress over time, from mild to severe. Because every person’s brain is different, the disease affects each person differently. Common symptoms include forgetting recent names, conversations, tasks and events. Finding the right word becomes difficult, and language skills decline, often with varying degrees of self-awareness. Patients frequently misplace everyday items such as keys, a purse or a phone. Families and loved ones may notice shifting moods, including anxiety, irritability, depression, frustration and, at times, paranoia and aggression. Patients may also gradually lose their sense of direction and their sense of time and date, and repetitive behaviors such leaving a faucet running, lights on, or doors and windows open or locked at the wrong times. Differences from patient to patient reflect the stage of the disease and the extent of damage to various areas and networks of the brain.
The main cause of Alzheimer’s disease is the sickness and death of cells in the cerebral cortex, the brain’s outer layer. One reason is the buildup of abnormal proteins, chiefly amyloid plaques. Alois Alzheimer observed these plaques in the brain of a dementia patient more than 120 years ago, hence the name Alzheimer’s disease. Amyloid plaques can be thought of as rust on an engine: the rust makes the engine creaky and corrodes its parts. In the same way, plaques interfere with brain function and damage brain cells, their connections and networks. Another toxic protein, called tau, forms tangles inside brain cells. Tau is a marker of brain injury and contributes to the damage.
As there is no cure for Alzheimer’s disease, and until recently there were no effective treatments, management begins with two steps. First, identify the signs and symptoms. A physician who specializes in dementia, or neuropsychological testing, can detect them. Second, confirm the diagnosis with lab tests and imaging studies. The most direct test is an amyloid PET scan, which measures how much amyloid plaque has built up in the brain, confirming the diagnosis of Alzheimer’s disease. Another option is analysis of cerebrospinal fluid, which involves inserting a needle into the spinal canal to collect a fluid sample that is tested for chemicals called biomarkers. A simpler method is a blood test, in which the presence of biomarkers can indicate a possible diagnosis of Alzheimer’s disease. Several blood tests are available, but they cannot be used in lieu of amyloid PET scan yet.
Despite extensive research into the clinical and biological aspects of this disease, effective treatments have long been unavailable. Memory-boosting medications that increase acetylcholine, and brain-protective drugs such as memantine, have offered only marginal benefit. Until 2023, no drugs that could alter the course of Alzheimer’s disease were available. That year, the FDA approved two drugs, Lecanemab and Donanemab. In clinical trials (including one led by Yale School of Medicine), patients treated for 18 months showed a noticeable reduction in amyloid plaques in the brain, and their cognitive decline was significantly slower than that of untreated patients. These drugs only slow a rapid decline; they do not restore lost function. That is why early detection and treatment are key.
There are some road bumps. The treatments are given intravenously and must be administered at an infusion center. A new form of drug delivery, weekly self-injection at home is now available. In addition, 10 to 20 percent of patients develop a reaction in the brain. As the drugs clear plaques from the brain, small brain arteries in some patients become leaky, causing swelling or tiny hemorrhages. Left unmonitored, these areas can cause brain injury, so a strict monitoring protocol is essential to assess and adjust treatment. This includes four MRIs in the first six months. The first few months of therapy are intense, with frequent infusions and monitoring and can be a logistical challenge for patients and families.
At our clinical behavioral neurology center at Yale School of Medicine, we treat more than 600 patients with positive results. The Yale Alzheimer’s Disease Research Center is one of only a few Alzheimer’s centers in the country funded by the National Institute on Aging. Yale New Haven Health’s new Adams Neurosciences Center, which will open to patients in early 2027, brings best in class care to the region for patients with neurological conditions.
Of course, a healthy lifestyle is key to a healthy brain. Social engagement, good sleep, daily exercise and a healthy diet low in sugar and salt are essential complements to any medical treatment. The goal for Alzheimer’s patients is to live safely, happily and independently in the setting of their choice. So, if you or a loved one is experiencing signs of the disease. Don’t wait to get diagnosed. Early intervention matters.
Sayed Ausim Azizi, MD, PhD, is a professor of Neurology at Yale School of Medicine and is the Clinical Chief of Behavioral Neurology & Memory Disorders with Yale Medicine and Yale New Haven Health. Opinions are his own.